广告
加载中

DeepSeek身后一位天津猛人

冯雨晨 2026-07-02 09:25
冯雨晨 2026/07/02 09:25

邦小白快读

EN
全文速览

本文核心讲了传统医疗企业九安医疗凭借新冠抗原检测红利获得巨额现金后,大范围布局AI创投领域的经过,核心干货如下:

1. 九安医疗原本是主营血压计的传统企业,2013-2019年连续7年扣非净利润亏损,2022年抓住海外抗原检测需求风口,一年盈利160.3亿元,股价五个月涨幅超11倍,账面最高沉淀140亿现金。

2. 九安医疗依托早年发起的校友创投基金切入投资,目前已经投资了DeepSeek、月之暗面、阶跃星辰、智元机器人、沐曦股份等一众顶流AI科技项目,投资沐曦已经获得超6倍浮盈,2025年投资收益达到28亿元,是当期主业收入的两倍多。

3. 需要注意的是,目前九安的投资收益全部来自AI上行周期,资管团队尚未经历完整牛熊,若AI估值回调,会对利润造成不小拖累。

本文给传统品牌厂商把握新机会、调整布局方向提供了诸多干货参考,内容如下:

1. 行业趋势参考:当前传统成熟主业普遍增长放缓,AI赛道处于明确的上行周期,传统品牌在获得超额现金流后,布局AI创投可以对冲主业周期风险,获得远超主业的投资收益,目前已有九安医疗、汤臣倍健、莲花控股等多家传统品牌布局AI赛道。

2. 决策能力参考:九安医疗在偶然获得抗原风口信息后,快速决策全力推进,10个月拿下美国FDA认证,成为美国市场最大供应商,这种快速抓住需求缺口的决策能力,值得所有品牌商学习。

3. 风险提示:当前AI赛道估值处于高位,投资收益波动大,传统品牌布局需要警惕周期风险,九安资管团队尚未经历完整牛熊考验,后续业绩存在不确定性。

本文给各类中小卖家、企业经营者揭示了当前市场的新机会与潜在风险,干货整理如下:

1. 机会方向:当前AI产业处于爆发上行期,是明确的增长风口,卖家如果在原有主业积累了富余现金流,可通过布局AI相关创投项目分享行业红利,已有多家传统领域企业通过这种方式获得了远超主业的收益。

2. 可行入局路径:可以参考九安医疗的路径,先从依托人脉资源参与产业基金做起,逐步过渡到直接参投优质项目、发起科创母基金,逐步搭建自己的投资版图,门槛相对较低,也能依托专业机构降低投资风险。

3. 风险提示:目前AI赛道整体估值偏高,若后续行业行情回调,投资收益可能从利润来源变成业绩拖累,投资者需要提前做好风险应对,不要过度加杠杆投入投资业务。

本文给传统生产工厂把握新商业机会、推进业务升级提供了参考干货,整理如下:

1. 商业机会:AI产业当前处于爆发上行周期,传统工厂不需要直接转型做AI业务,就可以通过一级市场投资参与AI产业红利,消化富余现金流,获得比扩产主业更高的收益。九安医疗作为传统制造型企业,目前投资收益已经是主业收入的两倍多,验证了这种路径的可行性。

2. 切入路径参考:传统工厂可以依托本地产业资源、人脉资源发起或者参与创投基金,比如九安依托天津大学校友资源发起北洋海棠基金,反而获得了优质项目的优先投资机会,门槛比直接做投资低很多。

3. 启示与风险:传统工厂在获得一次性红利后,不要盲目扩产已经增长见顶的主业,可以适当布局新赛道分享红利,但也要控制投资比例,警惕AI赛道的周期波动风险,避免影响主业正常运转。

本文给创投、咨询等产业服务商揭示了行业新趋势与新机会,干货整理如下:

1. 行业发展新趋势:越来越多传统上市企业手握充沛的闲置现金流,由于主业增长乏力,都有布局高增长新赛道的投资需求,传统企业正在成为一级市场重要的新增LP来源,AI是当前传统企业布局的核心方向。

2. 客户核心痛点:传统企业有投资需求,但缺乏直接投资优质AI项目的渠道和能力,需要专业服务商对接项目、搭建投资主体,帮他们完成布局。

3. 解决方案参考:服务商可以围绕传统企业的需求,在传统企业聚集地注册落地专门的投资主体,对接优质AI项目,匹配资金需求,比如文中砺思资本、拾象科技都在九安所在地天津注册新主体,对接九安的投资资金,获得了业务合作机会,同时也要帮客户做好风险提示,应对AI赛道的周期波动。

本文给科创平台、创投平台等平台型企业揭示了当前的市场需求与发展方向,干货整理如下:

1. 市场需求:当前大量手握富余现金流的传统上市公司,有强烈的布局AI赛道、分享产业红利的投资需求,这给各类科创、创投平台带来了新的业务增长机会,平台可以对接传统企业资金和AI初创项目,获得新的营收来源。

2. 可参考运营做法:平台可以依托地方产业资源、人脉资源发起科创母基金,吸引头部传统企业出资,比如天津天开科创平台联合九安医疗发起规模50亿元的天开九安海河海棠科创母基金,九安出资不超过35.6亿元,成为最大投资方,实现了平台、资金、项目的多方共赢。

3. 风险规避要点:当前AI赛道估值处于高位,波动较大,平台在招商和运营过程中,要充分提示周期风险,帮助投资方合理配置资产,避免后续估值回调引发的纠纷,保障平台长期稳定运营。

本文给产业研究人员提供了当前国内产业界的新动向与值得研究的新问题,干货整理如下:

1. 产业新动向:当前国内产业界出现了一种新的商业模式,传统制造业、消费业上市公司在主业获得超额现金流后,不选择扩产主业,而是将大部分资金用来布局一级市场的AI赛道,靠投资新赛道获得利润增长,除九安医疗外,汤臣倍健、莲花控股、养元饮品等多家传统企业都采用了这种模式,成为AI创投领域一股新的资本力量。

2. 需要研究的新问题:这种商业模式的可持续性尚未得到验证,目前所有收益都来自AI赛道的上行周期,九安医疗的投资团队建立仅4年,尚未经历完整的牛熊市周期,一旦AI赛道估值回调,会对上市公司利润造成多大冲击,传统企业做跨行业投资的能力边界在哪里,这些都是值得深入研究的新产业问题,对预判未来产业发展走向有重要意义。

返回默认

声明:快读内容全程由AI生成,请注意甄别信息。如您发现问题,请发送邮件至 run@ebrun.com 。

我是 品牌商 卖家 工厂 服务商 平台商 研究者 帮我再读一遍。

Quick Summary

This article details how iHealth, a traditional healthcare company, expanded aggressively into AI venture capital after generating massive cash flows from the COVID-19 antigen testing boom. Key takeaways are as follows:

1. Originally a traditional medical device firm focused on blood pressure monitors, iHealth posted seven consecutive years of negative core net profit between 2013 and 2019. It capitalized on the overseas surge in demand for antigen testing in 2022, earning a net profit of 16.03 billion yuan in one year. Its share price rose more than 11-fold over five months, leaving the company with a peak cash balance of 14 billion yuan.

2. iHealth entered the investment space through an alumni venture fund it launched years ago, and has already invested in a roster of high-profile AI startups including DeepSeek, Moonshot AI, StepGlide AI, Zhipu AI, and Muxi. Its investment in Muxi has already generated an unrealized gain of more than 6x, and the company is projected to record 2.8 billion yuan in investment income by 2025—more than twice the revenue from its core business in the same period.

3. It is important to note that all of iHealth’s investment returns to date have come amid the current upswing in the AI cycle, and its asset management team has never navigated a complete bull-bear market cycle. A valuation correction in AI could weigh heavily on its profitability.

This article offers actionable insights for traditional brand manufacturers looking to capture new opportunities and adjust their strategic positioning. Key takeaways are as follows:

1. Industry trend reference: Growth has slowed across most traditional, mature core businesses, while the AI sector is in a clear upcycle. Traditional brands that earn excess cash flow can hedge against core business cyclical risk by investing in AI venture capital, and generate investment returns far exceeding those from their original operations. Multiple traditional brands including iHealth, By-Health, and Lianhua Holding have already entered the AI space this way.

2. Decision-making benchmark: After learning of the antigen testing opportunity, iHealth made a quick decision to commit full resources to the project, securing U.S. FDA approval in 10 months and becoming the largest supplier in the U.S. market. This ability to rapidly capitalize on unmet demand is a lesson for all brand owners.

3. Risk warning: AI sector valuations are currently at elevated levels, and investment returns are highly volatile. Traditional brands pursuing AI investments need to watch out for cyclical risk. iHealth’s investment team has yet to prove itself through a full market cycle, leaving its future performance uncertain.

This article outlines new market opportunities and potential risks for small and medium-sized sellers and business operators. Key takeaways are as follows:

1. Opportunity direction: The AI industry is currently in a booming upcycle and represents a clear growth tailwind. Sellers that have accumulated excess cash flow from their existing core businesses can capture industry growth by investing in AI-related venture projects, and multiple traditional firms have already earned far higher returns through this approach than from their core operations.

2. Accessible entry path: Sellers can follow iHealth’s example: start by leveraging personal and professional networks to participate in industry funds, then gradually move to direct co-investment in high-quality projects and launch your own tech-focused fund of funds, to build out your investment portfolio step by step. This approach has relatively low barriers to entry and allows you to reduce investment risk by partnering with professional institutions.

3. Risk warning: Overall AI sector valuations are currently elevated. If the market corrects later, investment gains could turn into a drag on performance. Investors should prepare risk mitigation plans in advance and avoid overleveraging to fund investment activities.

This article offers insights for traditional manufacturing factories looking to capture new business opportunities and upgrade their operations. Key takeaways are as follows:

1. Business opportunity: The AI industry is currently in a strong upcycle. Traditional factories do not need to directly pivot into AI operations to capture AI industry growth: they can participate through private market investment to deploy excess cash and earn higher returns than expanding capacity in their core business. As a traditional manufacturing firm, iHealth’s investment income is already more than twice its core business revenue, proving the feasibility of this path.

2. Entry path reference: Traditional factories can launch or participate in venture funds by leveraging local industry and personal connections. For example, iHealth launched the Beiyang Haitang Fund through Tianjin University alumni networks, which gave it priority access to high-quality projects at a far lower entry barrier than building an in-house investment operation from scratch.

3. Insights and risks: After earning one-off windfall profits, traditional factories should not blindly expand capacity in mature, stagnant core businesses. They can allocate a portion of capital to capture growth from new sectors, but should control their investment share to guard against the cyclical volatility of the AI sector and avoid disrupting operations of their core business.

This article outlines new industry trends and opportunities for venture capital, consulting, and other industry service providers. Key takeaways are as follows:

1. New industry trends: A growing number of traditional public companies hold large amounts of idle cash. Faced with stagnant growth in their core businesses, they have strong demand to invest in high-growth new sectors, and traditional companies have become an important new source of limited partner capital for the private market, with AI the primary focus of their investment activity.

2. Core client pain points: Traditional companies have investment demand but lack the channels and capabilities to directly invest in high-quality AI projects, so they rely on professional service providers to source deals, set up investment vehicles, and support their market entry.

3. Solution reference: Service providers can set up dedicated investment entities in regions with a high concentration of traditional enterprises to match client capital with high-quality AI projects, to meet this unmet demand. For example, Lisi Capital and Shixiang Technology both set up new local entities in Tianjin, iHealth’s headquarters, to access iHealth’s investment capital and secure new business. Service providers should also clearly communicate risks to clients and help them prepare for the cyclical volatility of the AI sector.

This article outlines current market demand and development directions for tech and venture capital platforms. Key takeaways are as follows:

1. Market demand: A large number of traditional public companies hold excess cash and have strong demand to invest in the AI sector to capture industry growth. This creates new growth opportunities for tech and venture capital platforms, which can connect traditional corporate capital with AI startups to open new revenue streams.

2. Operational best practices: Platforms can leverage local industry and network resources to launch technology-focused funds of funds, and attract capital from leading traditional enterprises. For example, Tianjin Tiankai Innovation Technology platform partnered with iHealth to launch the 5 billion yuan Tiankai iHealth Haihe Haitang Innovation Fund of Funds, where iHealth committed up to 3.56 billion yuan as the largest investor. The arrangement delivered win-win outcomes for the platform, capital providers and startups.

3. Risk mitigation: AI sector valuations are currently elevated and highly volatile. Platforms should clearly communicate cyclical risks during fundraising and operations, help investors build appropriately diversified portfolios, and avoid disputes stemming from future valuation corrections to support long-term, stable operations.

This article outlines new industry developments and underexplored research questions for industry analysts. Key takeaways are as follows:

1. New industry trend: A new business model has emerged among Chinese industry incumbents: public companies in traditional manufacturing and consumer sectors that earn excess cash flow from their core businesses are choosing not to reinvest in expanding their original operations, instead allocating the majority of capital to AI investments in the private market to drive profit growth. Beyond iHealth, a number of traditional firms including By-Health, Lianhua Holding, and Yangyuan Drink have adopted this model, becoming an important new source of capital in AI venture investing.

2. Key research questions: The long-term sustainability of this model has yet to be tested. All returns to date have been generated during the AI upcycle; iHealth’s investment team was only founded four years ago and has never navigated a full market cycle. Key open questions for further research include how much a correction in AI valuations would hit public companies’ profits, and where the capability boundary lies for traditional firms pursuing cross-sector investment. Answering these questions is critical to forecasting the future trajectory of Chinese industry.

Disclaimer: The "Quick Summary" content is entirely generated by AI. Please exercise discretion when interpreting the information. For issues or corrections, please email run@ebrun.com .

I am a Brand Seller Factory Service Provider Marketplace Seller Researcher Read it again.

DeepSeek首轮融资终近尾声,“谁成为了少数上车的人”以及“为什么是他们”正在引发集体探究。出乎意料,九安医疗的身影浮现在投资阵容中。

众所周知,九安医疗很有钱。2022年靠海外新冠抗原检测试剂盒需求爆发,一年就赚了160个亿,这之后,九安医疗掌门人刘毅没有选择大肆扩产主业,而是将绝大部分资金用来投资——出手月之暗面、阶跃星辰,还把自变量机器人、智元机器人、松延动力等一众明星项目网罗其中。

看似不务正业,但成绩相当亮眼:2025年,九安医疗投资收益与公允价值变动合计逾28亿元,是当期主营业务收入的两倍有余。

目睹着智谱冲上万亿市值,恐怕没有人比九安医疗更期待后面的大模型上市潮。

那年突然暴富,账上多了140亿现金

很难不回味“九安大帝”神姿。

2021年11月15日至2022年4月15日,九安医疗在102个交易日内出现高达38个涨停,其中最大连续涨停天数为9天,区间最高涨幅为惊人的1105%。与之相对应,2022年九安医疗盈利160.3亿元——比上市十余年来的营收总和还要多。

此番暴涨,猝不及防。毕竟此前很多年里,二级市场对九安医疗的印象无非是一卖血压计的,业绩普普通通。

命运的转折,源自2020年底一次会后闲聊。

彼时,九安医疗的iHealth红外额温计成了防疫筛查的重要工具,并在2020年小赚了2.4亿元。之所以说是小赚,是因为自2010年上市以来,九安医疗业绩一直有些堪忧——2013年至2019年扣非净利润连续7年亏损,同步地,其股价在2015年至2019年间跌幅一度超9成。

这里不得不铺垫一个细节,九安医疗创始人刘毅是天津大学校友,毕业后在天津创业更发家于天津,2017年在其五十岁之际接手了天津大学天津校友会会长。他提出一个想法:能不能做一支校友基金,专门投资学生、老师和校友的创业项目?于是2019年,刘毅联合近20位天大校友企业家,发起设立北洋海棠创投基金。

或许刘毅自己也没想到,这份基金帮校友的初心很快以意想不到的方式回馈到了他自己的身上。

2020年12月,北洋海棠基金开投决会,刘毅在场。结束后几位企业家和投资人闲聊,时任天创资本的魏宏锟讲了一个案例:他们投的一家新冠抗原试剂盒企业,9月份之前全年销售额才1000多万,9月之后的四个月里,卖了42个亿。

这给刘毅带来了极大的冲击,乃至反思——九安医疗的额温计在防疫上贡献了最大数量,为什么口罩和抗原反而浅尝辄止?

适逢美国刚批下来第一家新冠抗原试剂盒,九安医疗迅速决策全力推进,10个月后拿下FDA认证,最终在美国市场成为了最大的供应商。刘毅后来描述那段疯狂的日子:最多时超过6万人,上百家工厂在为九安做产品包装,一天有八架飞机将试剂盒空运到美国,最高日产2600万只。

仅2022年一年,九安医疗就创造了182.22亿的经营活动现金流净额,当年,其账面货币资金一度高达惊人的140亿元。

也投月之暗面,揭开一张隐秘版图

从此,手握巨额现金的九安医疗坐上了投资人牌桌。

今年6月,多家参与的投资机构私下分享了DeepSeek的融资信息:创始人梁文锋,腾讯、宁德时代、以及网易、京东、Monolith砺思资本、IDG资本、正心谷投资、拾象科技、国家人工智能产业投资基金等参与方一一出炉。

九安医疗的身影顺着脉络浮现。投资方拾象科技在5月新设主体天津拾象投资合伙企业(有限合伙),15.1亿元注册资本与本次传出对DeepSeek的投资金额正巧对应,其中,九安香港出资7.5亿元。

另一边,砺思资本近期也设立了天津砺思星灵创业投资合伙企业(有限合伙)、天津砺思明棠企业管理咨询合伙企业(有限合伙)等多家主体——这些主体注册地址均在天津,结合九安医疗核心阵地也在天津,不由引发遐想。

回头看,大概从2022年下半年开始,九安医疗就作为LP在一级市场上出资了Monolith砺思资本、济峰资本、元生创投、鼎峰资本、清智资本、耀途资本、奇绩创坛、九合创投、英诺等多只基金。

后来“渐入佳境”,设立九尚创投、九棠创投主动布局一级市场投资。印象较深刻的是2024年,九安医疗参与发起规模达50亿元的天开九安海河海棠科创母基金,其中九安香港单笔出资不超过35.6亿元,是其最大的一笔投资。

在外界的印象中,九安医疗首次涉足AI应是对月之暗面Kimi的投资。

那是2023年8月,九安医疗与月之暗面签署投资协议,首次投资约1000万美元;2024年3月,九安医疗追加投资约2000万美元。最新消息,月之暗面正在计划最高20亿美元的新一轮融资,投后估值可达300亿美元。

如此,九安医疗收获注定不菲。近期刘毅在21世纪经济报道采访中提到:“决定投资月之暗面时杨植麟是一个31岁的小伙子,当时以6亿美金投进去的。”

当中还有一个细节,九安医疗所出资的Monolith砺思资本正是月之暗面的核心投资方。一个月前,Monolith砺思资本创始合伙人曹曦在2026投资界SuperLink大会聊起,“第一期基金有20%投到了Kimi”。

不止月之暗面。2025年初,九安医疗通过科创母基金完成对沐曦股份1亿元投资,同年12月沐曦股份科创板上市,首日一度暴涨近700%,彼时九安医疗浮盈超过6倍。此外,自变量机器人、智元机器人、松延动力、穹彻智能、生数科技等这些热门具身智能、半导体项目构成了九安医疗极具魅力的科技投资版图。

标的池还在增加。6月1日,九安医疗公告出资1.03亿元认购海棠同慧创业投资合伙企业(有限合伙)份额,该基金总规模4.12亿元,专项用于投资人工智能大模型公司阶跃星辰。旋即6月23日,具身智能企业正行创新宣布完成近亿美元的天使轮融资,投资方名单中出现九安医疗。

一级之外,现金丰沛的九安医疗也配置了二级市场资产。几年间,持仓从最初的小米、小鹏、理想、蔚来扩展到腾讯控股、美国国债、标普500ETF、半导体ETF和纳斯达克100ETF。整个2025年,九安医疗以公允价值计量的金融资产高达218.05亿元,其中证券投资总计59.64亿元。

“奖励那些不务正业的孩子”,投在上行周期

一家传统公司突然挣了大钱,通常会做两种选择:扩张主业或把钱投出去。

前者往往会沉淀为固定资产,后者更多会反映到金融资产和投资收益上。纵观九安医疗固定资产规模,从2021年的1.77亿元增长到今天的4.70亿元,相比其超200亿元的金融资产规模,相形见绌中答案显而易见。

某种程度上,这种选择背后映射着产业景气度的迁徙——九安医疗所在的体外诊断行业在疫情红利退潮后收缩明显,而2022年至今,AI浪潮以及对应产业链的爆发有目共睹。

和九安医疗一样,把手里的流动性投到新上行周期里的消费赛道上市公司也不少见。6月18日,汤臣倍健宣布计划以自有5000万资金投资AI芯片创企原粒半导体,更早前,汤臣倍健还通过自投或基金通道分别投资了阶跃星辰、月之暗面、XGTECH、AI主题创投基金(砺思星灵)等AI方向。据悉,本次DeepSeek融资的投资方背后,也有汤臣倍健出资。

再往前看,“味精大王”莲花控股在2025年8月先是携手浙江大学研发半导体封装材料,今年5月,莲花控股宣布以3亿元投资大模型企业阶跃星辰,补齐大模型拼图;此外,2025年4月,“六个核桃”母公司养元饮品公告出资16亿元投资长江存储母公司。

类似故事很多。“市场在奖励那些不务正业的孩子”,如此戏谑流传。

但风险也很诚实。

九安医疗这几年的科技投资固然身手漂亮,但恰逢在AI行情的超级上行期。九安医疗2025年财报中,投资收益与公允价值变动合计28.32亿元,2026年第一季度为4.49亿元,均远超当期总营收并构成利润主要来源。

倘若后续AI赛道估值回调,势必会影响投资项目的价值,那么曾经的贡献亦可能变成同等量级的拖累。无法忽视的是,九安医疗资管团队自2022年建立起来,至今还尚未经历一个完整的牛熊市周期。

那笔泼天财富,没有把九安医疗困在过去。但在风口之上赚钱和穿越风暴赚钱,是两种截然不同的能力。

注:文/冯雨晨,文章来源:投资界(公众号ID:pedaily2012),本文为作者独立观点,不代表亿邦动力立场。

文章来源:投资界

广告
微信
朋友圈

FAQ回顾

九安医疗的科技投资布局涉及哪些领域?

九安医疗2022年起依托充足现金流布局一二级市场投资,一级市场覆盖人工智能大模型、具身智能、半导体等领域,投了DeepSeek、月之暗面、阶跃星辰、智元机器人等明星项目,2025年投资收益与公允价值变动合计超28亿元。

九安医疗的大额可投资资金来源是什么?

2022年九安医疗成为美国市场最大的新冠抗原检测试剂盒供应商,全年盈利160.3亿元,经营活动现金流净额达182.22亿元,账面货币资金最高达140亿元,为后续科技投资积累了充足储备。

有哪些消费类上市公司在布局科技领域投资?

除九安医疗外,多家消费赛道上市公司都在布局AI等科技领域投资:汤臣倍健投资原粒半导体、阶跃星辰等AI相关项目,莲花控股3亿元投资大模型企业阶跃星辰,养元饮品出资16亿元投资长江存储母公司。

九安医疗的科技投资存在什么风险?

九安医疗当前投资收益主要受益于AI行情上行周期,若后续AI赛道估值回调,投资项目价值将受到影响,且其资管团队2022年才建立,尚未经历完整牛熊市周期,存在一定投资不确定性。

这么好看,分享一下?

朋友圈 分享

APP内打开

赞 +1
+1
微信好友 朋友圈 新浪微博 QQ空间
关闭
收藏成功
发送
/140 0